Revenue segments as reported by the company.

Instruments & Accessories

Systems

Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intuitive Surgical

Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. Its products include Da Vinci and Ion. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intuitive Surgical reports robust Q4 performance and eyes future growth

Intuitive Surgical's Q4 2022 showcased strong performance and growth in procedures and system placements.
While facing challenges like macroeconomic uncertainty and supply chain costs, the company is poised for continued innovation.
Opportunities lie in expanding markets, advancing technology, and improving surgical outcomes through collaboration.
Investments in industrial scale, automation, and platform advancements signal a strategic focus on future growth.

Intuitive Surgical (ISRG) reports robust Q1 performance and growth outlook

Intuitive Surgical (ISRG) delivered strong Q1 results with revenue up 14% and exceeding procedure growth expectations.
While facing challenges in manufacturing and supply chain, the company is focusing on R&D progress and inventory replenishment.
The outlook for 2023 looks promising with increased procedure growth forecasts and a focus on improving patient outcomes and market expansion.
Overall, Intuitive Surgical (ISRG) is well-positioned to capitalize on opportunities for growth and innovation in the robotic surgery market.

Intuitive Surgical excels in Q2 performance, eyes AI opportunities

Intuitive Surgical's Q2 2023 performance showcased strong revenue growth, procedure increases, and a focus on healthcare improvement.
The company's strengths include innovative ecosystem investments, commitment to patient outcomes, and advanced surgical technologies.
Challenges include market disruptions from new drugs, expense management, and adapting to changing healthcare landscapes.
Opportunities in AI, market expansion, and new procedures position Intuitive Surgical for continued growth and innovation.

Intuitive Surgical excels in Q3, eyes global expansion and margin growth

Intuitive Surgical's Q3 performance reflects strong growth and strategic focus on innovation and market expansion. Despite challenges in specific procedure categories and pricing dynamics, the company is well-positioned to capitalize on opportunities for growth and margin improvement.

Intuitive Surgical posts strong 2023 results, da Vinci 5 launch ahead

Intuitive Surgical's 2023 performance reflects strong revenue growth, operational excellence, and a strategic focus on innovation with the upcoming da Vinci 5 launch.
While facing challenges in operating margin pressure and supply chain issues, the company is well-positioned to capitalize on opportunities in soft tissue surgery, big data integration, and leased placements.
Investors should monitor how Intuitive Surgical navigates the launch of da Vinci 5, manages operational challenges, and leverages growth opportunities to sustain its market leadership.
Overall, Intuitive Surgical's Q4 earnings call highlights a resilient business model, customer-centric approach, and a commitment to advancing surgical technology for better patient outcomes.

Intuitive Surgical posts robust Q1 results amidst global market challenges

Intuitive Surgical delivered strong Q1 results with notable procedure and revenue growth, despite challenges in certain markets.
The company's focus on newer platforms, operational efficiency, and strategic outlook for 2024 positions it for continued success.
Addressing challenges and seizing opportunities in global markets and product innovation will be key for sustained growth and competitiveness.

Intuitive Surgical excels in Q2, eyes global expansion and innovation

Intuitive Surgical's Q2 performance reflects strength in procedure growth and system platform advancements.
The company's commitment to innovation and value creation positions them well for future success.
Challenges include sustaining margins and navigating market dynamics, while opportunities lie in expansion and innovation.
Overall, Intuitive Surgical's focus on growth, technology, and patient care sets a positive trajectory for the future.

Intuitive Surgical excels in Q3 with strong growth and innovation

Intuitive Surgical's Q3 2024 performance reflects a company in a strong position with notable achievements in procedures, financials, and technological advancements. While facing challenges in margin progression and international expansion, the company is well-positioned to leverage opportunities in innovation and customer insights.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Axon Enterprise

Twenty-First Century Fox

Sprouts Farmers Markets

United Continental Hlds

These five stocks have provided 50% returns year to date. Despite the rally, their favorable Zacks Rank indicates more room to run.

5 Non-Tech Nasdaq Composite High Flyers to Buy for More Gains Ahead

Intuitive Surgical has become a leader for numerous procedures, and we expect it to continue its growth. The company is seeing double-digit growth both in systems and consumables driving revenue. We expect the company to continue its growth and returns making it a valuable investment.

Intuitive Surgical Is Breaking Ground

Here is how Intuitive Surgical, Inc. (ISRG) and Atossa Genetics Inc. (ATOS) have performed compared to their sector so far this year.

Is Intuitive Surgical (ISRG) Outperforming Other Medical Stocks This Year?

Zacks.com users have recently been watching Intuitive Surgical (ISRG) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know

Intuitive Surgical has maintained an uptrend so far this year on the back of robust da Vinci portfolio performance. The stock also gained during the past month.

Will ISRG Stock Continue Its Uptrend After Gaining 9.9% in a Month?

Netflix

Royal Caribbean Cruises

These stocks may have done well this year, but here's the case for owning them for another two decades or more.

3 Soaring Stocks to Hold for the Next 20 Years

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Wall Street Analysts Think Intuitive Surgical (ISRG) Is a Good Investment: Is It?

Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.

Intuitive Surgical, Inc. (ISRG) Is a Trending Stock: Facts to Know Before Betting on It

Abbott Labs

UnitedHealth Group

Investors looking for health-related buy-and-hold stocks must look no further than this list. The stocks on this list are market leaders in healthcare, producing sustainable growth with healthy balance sheets, impressive value, and broad market support.

These Are The Top Health Stocks to Own for Buy-and-Hold Investing

We believe Intuitive Surgical (NASDAQ: ISRG) stock is positioned to grow its value nearly 10x in the long run as its robotic surgical business revolutionizes the healthcare sector — tracing a trajectory similar to what AI posterchild Nvidia's stock has witnessed over recent years (Buy, Sell, or Hold Nvidia Stock?). Here's why.

ISRG Stock To $5,000

Pfizer

These two stocks have moved in different directions this year, but that shouldn't mean much to long-term investors.

Got $1,000? 2 Healthcare Stocks to Buy and Hold Forever.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Intuitive Surgical (ISRG) Is Considered a Good Investment by Brokers: Is That True?

Amazon

Costco

Paycom Software

Vanguard Information Technology ETF

Each has an impressive history of share price performance and great prospects for further growth.

5 Monster Stocks to Hold for the Next 5 to 25 Years

Intuitive Surgical continues to be one of the market's hottest stocks.

Up 800% the Past Decade, Can the Momentum Continue for This Hot Stock?

General Mills

Tesla

Buying oversold stocks is not a question of one man's trash being another's treasure. In many cases, it's simply the ability to look at specific fundamental or technical indicators as a way to identify stocks that are buying opportunities.

Oversold But Ready to Rally: 5 Stocks to Watch Now

Technical traders and technically-minded investors will rejoice after a look at the Intuitive Surgical NASDAQ: ISRG price chart. The market for this leading med-tech company has produced a strong rally since summer, rising $115 from the low to the high in September, or about 30%, and now signaling that the trend will continue for this healthcare company.

Intuitive Surgical Confirms Bullish Flag: 25% to 30% Upside Ahead

While the top- and bottom-line numbers for Intuitive Surgical (ISRG) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Compared to Estimates, Intuitive Surgical (ISRG) Q3 Earnings: A Look at Key Metrics

United States Cellular

A leading robotic surgery stock hit a new high on Friday and is in a buy zone. A telecom stock also hit a new high.

Robotic Surgery Leader, Mobile Carrier Jump To New Highs

Intuitive Surgical, Inc. ISRG Thursday reported upbeat earnings for its third quarter.

Intuitive Surgical Posts Q3 Earnings Beat, These Analysts Raise Forecasts On DV5 Uptake

Shares of Intuitive Surgical (ISRG) hit an all-time high Friday, a day after the medical device maker posted better-than-expected results on more use of its da Vinci minimally invasive surgical devices.

Intuitive Surgical Stock Hits Record High on da Vinci Device Demand

ISRG's third-quarter results reflect a healthy demand for procedures. Higher pricing boosts procedure sales.

Intuitive Surgical Q3 Earnings Beat, Procedures Robust

Major indexes faded late in Thursday's trading, with the Nasdaq Composite finishing up just .036%.

Live Market Updates: Nasdaq Composite Up | NFLX & ISRG Crush Earnings

I reiterate a 'Sell' rating on Intuitive Surgical with a fair value of $350 per share due to its hefty valuation. The Da Vinci 5 robot rollout in mid-2025 is a major catalyst, with significant growth potential from innovative technology and positive surgeon feedback. Despite strong leadership and market position, ISRG's overvaluation and high WACC of 13% justify the 'Sell' rating.

Intuitive Surgical Q3: Da Vinci 5 Robot Set For 2025, But Overvalued

Intuitive Surgical, Inc. (NASDAQ:ISRG ) Q3 2024 Earnings Conference Call October 17, 2024 4:30 PM ET Company Participants Brandon Lamb - Investor Relations Gary Guthart - Chief Executive Officer Dave Rosa - President Jamie Samath - Chief Financial Officer Conference Call Participants Travis Steed - Bank of America Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan David Roman - Goldman Sachs Rick Wise - Stifel Adam Maeder - Piper Sandler Brandon Vazquez - William Blair Matt Miksic - Barclays Operator Thank you everyone for standing by and welcome to the Intuitive Third Quarter 2024 Earnings Release. Now at this time all participants are on a listen-only mode.

Intuitive Surgical, Inc. (ISRG) Q3 2024 Earnings Call Transcript

Earnings of $5.40 per share for NFLX surged past the $5.09 in the Zacks consensus, demonstrating +45% growth year over year.

News for Intuitive Surgical Stock (ISRG)